Literature DB >> 20332382

Incidence, predictors, and prognostic implications of hospitalization for late bleeding after percutaneous coronary intervention for patients older than 65 years.

Dennis T Ko1, Lingsong Yun, Harindra C Wijeysundera, Cynthia A Jackevicius, Sunil V Rao, Peter C Austin, Jean-François Marquis, Jack V Tu.   

Abstract

BACKGROUND: Previous data on bleeding after percutaneous coronary intervention (PCI) have been obtained primarily from randomized trials that focused on in-hospital bleeding. The incidence of late bleeding after PCI, its independent predictors, and its prognostic importance in clinical practice has not been fully addressed. METHODS AND
RESULTS: We evaluated 22 798 patients aged >65 years who underwent PCI from December 1, 2003, to March 31, 2007, in Ontario, Canada. Cox proportional hazard models were used to determine factors associated with late bleeding, which was defined as hospitalization for bleeding after discharge from the index PCI, and to estimate risk of death or myocardial infarction associated with late bleeding. We found that 2.5% of patients were hospitalized for bleeding in the year after PCI, with 56% of bleeding episodes due to gastrointestinal bleed. The most significant predictor of late bleeding was warfarin use after PCI (hazard ratio [HR], 3.12). Other significant predictors included age (HR, 1.41 per 10 years), male sex (HR, 1.24), cancer (HR, 1.80), previous bleeding (HR, 2.42), chronic kidney disease (HR, 1.93), and nonsteroidal antiinflammatory drug use (HR, 1.73). After adjusting for baseline covariates, hospitalization for a bleeding episode was associated with a significantly increased 1-year hazard of death or myocardial infarction (HR, 2.39; 95% CI, 1.93 to 2.97) and death (HR, 3.38; 95% CI, 2.60 to 4.40).
CONCLUSIONS: Hospitalization for late bleeding after PCI is associated with substantially increased risk of death and myocardial infarction. The use of triple therapy (i.e., aspirin, thienopyridine, and warfarin) is associated with the highest risk of late bleeding.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20332382     DOI: 10.1161/CIRCINTERVENTIONS.109.928721

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  14 in total

1.  Impact of an integrated treatment algorithm based on platelet function testing and clinical risk assessment: results of the TRIAGE Patients Undergoing Percutaneous Coronary Interventions To Improve Clinical Outcomes Through Optimal Platelet Inhibition study.

Authors:  Jaya Chandrasekhar; Usman Baber; Roxana Mehran; Melissa Aquino; Samantha Sartori; Jennifer Yu; Annapoorna Kini; Samin Sharma; Carsten Skurk; Richard A Shlofmitz; Bernhard Witzenbichler; George Dangas
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

2.  Triple Antithrombotic Therapy and Outcomes in Post-PCI Patients Undergoing Non-cardiac Surgery.

Authors:  Javier A Valle; Laura Graham; Aerin DeRussy; Kamal Itani; Mary T Hawn; Thomas M Maddox
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

3.  Postdischarge Bleeding After Percutaneous Coronary Intervention and Subsequent Mortality and Myocardial Infarction: Insights From the HMO Research Network-Stent Registry.

Authors:  Javier A Valle; Susan Shetterly; Thomas M Maddox; P Michael Ho; Steven M Bradley; Amneet Sandhu; David Magid; Thomas T Tsai
Journal:  Circ Cardiovasc Interv       Date:  2016-06       Impact factor: 6.546

4.  Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the National Heart, Lung, and Blood Institute dynamic registry.

Authors:  Jonathan R Enriquez; Shailja V Parikh; Faith Selzer; Alice K Jacobs; Oscar Marroquin; Suresh Mulukutla; Vankeepuram Srinivas; Elizabeth M Holper
Journal:  Chest       Date:  2011-04-28       Impact factor: 9.410

5.  Predictors of warfarin-induced bleeding in a South Indian cardiology unit.

Authors:  Haritha Nekkanti; Uday Venkant Mateti; Rajesh Vilakkathala; Thiyagu Rajakannan; Surulivelrajan Mallayasamy; Ramachandran Padmakumar
Journal:  Perspect Clin Res       Date:  2012-01

6.  Practice patterns and trends in the use of medical therapy in patients undergoing percutaneous coronary intervention in Ontario.

Authors:  Pallav Garg; Harindra C Wijeysundera; Lingsong Yun; Warren J Cantor; Dennis T Ko
Journal:  J Am Heart Assoc       Date:  2014-08-13       Impact factor: 5.501

7.  Bleeding after percutaneous coronary intervention: can we still ignore the obvious?

Authors:  Mony Shuvy; Dennis T Ko
Journal:  Open Heart       Date:  2014-02-28

8.  Incidence and prognostic impact of post discharge bleeding post acute coronary syndrome within an outpatient setting: a systematic review.

Authors:  Nafiu Ismail; Kelvin P Jordan; Sunil Rao; Tim Kinnaird; Jessica Potts; Umesh T Kadam; Mamas A Mamas
Journal:  BMJ Open       Date:  2019-02-20       Impact factor: 2.692

9.  Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.

Authors:  Philip Urban; Roxana Mehran; Roisin Colleran; Dominick J Angiolillo; Robert A Byrne; Davide Capodanno; Thomas Cuisset; Donald Cutlip; Pedro Eerdmans; John Eikelboom; Andrew Farb; C Michael Gibson; John Gregson; Michael Haude; Stefan K James; Hyo-Soo Kim; Takeshi Kimura; Akihide Konishi; John Laschinger; Martin B Leon; P F Adrian Magee; Yoshiaki Mitsutake; Darren Mylotte; Stuart Pocock; Matthew J Price; Sunil V Rao; Ernest Spitzer; Norman Stockbridge; Marco Valgimigli; Olivier Varenne; Ute Windhoevel; Robert W Yeh; Mitchell W Krucoff; Marie-Claude Morice
Journal:  Eur Heart J       Date:  2019-08-14       Impact factor: 29.983

10.  Causes and predictors of early readmission after percutaneous coronary intervention among patients discharged on oral anticoagulant therapy.

Authors:  Mahesh K Vidula; Cian P McCarthy; Neel M Butala; Kevin F Kennedy; Jason H Wasfy; Robert W Yeh; Eric A Secemsky
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.